#Flash: Study finds, NOV03 is Safe & Efficacious in treatmen
NOV03 has a unique dual mode of action to address dry eye disease (DED) associated with meibomian gland dysfunction. A total of 336 DED patients were randomized in a 2:2:1:1 manner to NOV03 4 times daily (QID), NOV03 twice daily (BID), saline BID, and saline QID, respectively. Results showed that NOV03 showed pronounced improvement in various symptoms. Benefits on tCFS and symptoms started at 2 weeks after start of treatment. NOV03 was well tolerated with instillation site reactions below 3% in both treatment regimes.
NOV03 improves signs and symptoms in patients with highly symptomatic evaporative dry eye disease.

If you find this research insightful, please like, comment and share.

Source: https://journals.lww.com/corneajrnl/Fulltext/2021/09000/A_Randomized_Clinical_Study__SEECASE__to_Assess.12.aspx